Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography

Breast Cancer Research

Volumn 7, Issue 4, 2005, Pages 153-162

  Bénard, François ^a   Turcotte, Éric ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL 3 METHYL ETHER; ESTROGEN RECEPTOR; ETIDRONIC ACID TC 99M; FLUORODEOXYGLUCOSE F 18; MEMBRANE RECEPTOR; METALLOPROTEINASE INHIBITOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; SIGMA OPIATE RECEPTOR; TETROFOSMIN TC 99M; THALLIUM CHLORIDE TL 201;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; LYMPH NODE METASTASIS; MAMMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SCINTIMAMMOGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AMINO ACIDS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIGANDS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NUCLEOSIDES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BIOSYNTHESIS; RADIOPHARMACEUTICALS; RECEPTORS, ESTROGEN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 21044453202     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr1201     Document Type: Review

References (113)

1. Buist DS, Porter PL, Lehman C, Taplin SH, White E: Factors contributing to mammography failure in women aged 40-49 years. J Natl Cancer Inst 2004, 96:1432-1440.
2. Viale G, Bosari S, Mazzarol G, Galimberti V, Luini A, Veronesi P, Paganelli G, Bedoni M, Orvieto E: Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999, 85:2433-2438.
3. Altinyollar H, Kapucuoglu N, Pak I, Berberoglu U: Lymphatic mapping and sentinel lymphadenectomy in early stage breast carcinoma. J Exp Clin Cancer Res 2000, 19:141-144.
4. Weaver DL, Krag DN, Ashikaga T, Harlow SP, O'Connell M: Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000, 88: 1099-1107.
5. Hsieh PP Ho WL, Yeh DC, Liu TJ, Wu CC, Lin JH, Wang SJ: Histopathologic analysis of sentinel lymph nodes in breast carcinoma. Chung Hua I Hsueh Tsa Chih (Taipei) 2000, 63: 744-750.
6. Canadian Cancer Statistics 2005 [http://www.cancer.ca]
7. Fisher B, Osborne K, Margolese R, Bloomer W: Neoplasms of the breast. In Cancer Medicine. Vol. 1. 4th edition. Edited by Holland J, Blast R, Morton D, Frei E, Kuge D, Weichselbaum R. Baltimore Williams & Wilkins; 1997:2349-2429.
8. Jardines L, Callans LS, Torosian MH: Recurrent breast cancer: presentation, diagnosis, and treatment. Semin Oncol 1993, 20: 538-547.
9. Peters W: Management of metastatic breast cancer. Adv Intern Med 1995, 40:341-364.
10. Hustinx R, Benard F, Alavi A: Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 2002, 32:35-46.
11. Shields AF, Grierson JR, Dohmen BM. Machulla HJ, Stayanoff JC, Lawhorn-Grews JM, Obradovich JE, Muzik O, Mangner TJ: Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998, 4:1334-1336.
12. Kieswetter D, Kilbourn M, Landvatter S, Heiman D, Katzenellenbogen J, Welch M: Preparation of four fluorine-18-labeled estrogens and their selective uptake in target tissues of immature rats. J Nucl Med 1984, 25:1212-1221.
13. Liberman M, Sampalis F, Mulder DS, Sampalis JS: Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature. Breast Cancer Res Treat 2003, 80:115-126.
14. 99mTc-sestamibi in vitro. Anticancer Res 1997, 17:1833-1839.
15. Chiu ML, Kronauge JF, Piwnica-Worms D: Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 1990, 31:1646-1653.
16. Maublant JC, Zhang Z, Rapp M, Ollier M, Michelot J, Veyre A: In vitro uptake of technetium-99m-teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m-sestamibi and thallium-201. J Nucl Med 1993, 34:1949-1952.
17. Piwnica-Worms D, Chiu ML, Croop JM, Kronauge JF: Enhancement of Tc-99m-sestamibi accumulation in multidrug resistant (MDR) cells by cytotoxic drugs and MDR reversing agents. J Nucl Med 1993, 34:140P.
18. Palmedo H, Bender H, Grunwald F, Mallmann P, Zamora P, Krebs D, Biersack HJ: Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 1997, 24:1138-1145.
19. Yutani K, Shiba E, Kusuoka H, Tatsumi M, Uehara T, Taguchi T, Takai SI, Nishimura T: Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000, 24:274-280.
20. 99mTc-MIBI in the detection of axillary lymph node metastases of breast carcinoma. Acta Radiol 1999, 40:491-495.
21. Taillefer R, Robidoux A, Turpin S, Lambert R, Cantin J, Leveille J: Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer. J Nucl Med 1998, 39:459-464.
22. 99mTc-sestamibi scintimammography in patients with suspicious breast lesions: comparison of SPET and planar images in the detection of primary tumours and axillary lymph node involvement. Nucl Med Commun 1997, 18:839-845.
23. Cwikla JB, Buscombe JR, Kolasinska AD, Holloway B, Hilson AJ: Evaluation of scintimammography as an additional test to conventional mammography in detection of breast cancer [in Polish]. Ginekol Pol 2003, 74:362-370.
24. 99mTc-MIBI scintimammography in patients with breast microcalcifications. Breast 2004, 13:316-320.
25. Palmedo H, Biersack HJ, Lastoria S, Maublant J, Prats E, Stegner HE, Bourgeois P, Hustinx R, Hilson AJ, Bischof-Delaloye A: Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med 1998, 25:375-385.
26. Tiling R, Linke R, Kessler M, Untch M, Sommer H, Brinkbaumer K, Becker I, Hahn K: Breast scintigraphy using 99mTc-sestamibi - use and limitations [in German]. Nuklearmedizin 2002, 41:148-156.
27. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB: Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer 1999, 85:2410-2423.
28. 99mTc-MIBI. Acta Radiol 2003, 44:284-287.
29. 99mTc-Sestamibi uptake. Nucl Med Commun 2005, 26:9-15.
30. 99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer 2005, 103:680-688.
31. Kao CH, Tsai SC, Liu TJ, Ho YJ, Wang JJ, Ho ST, ChangLai SP: P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. Cancer Res 2001, 61:1412-1414.
32. Cwikla JB, Kolasinska A, Buscombe JR, Hilson AJ: Tc-99m MIBI in suspected recurrent breast cancer. Cancer Biother Radiopharm 2000, 15:367-372.
33. 18F]deoxyglucose. J Nucl Med 1978, 19:1154-1161.
34. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE: Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979, 6:371-388.
35. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 1991, 67:1544-1550.
36. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL: Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 1995, 36:1854-1861.
37. Clavo AC, Brown RS, Wahl RL: Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995, 36:1625-1632.
38. Higashi K, Clavo AC, Wahl RL: Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993, 34:414-419.
39. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001, 42:9-16.
40. 18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998, 25:1429-1434.
41. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL: Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993, 187:743-750.
42. Crowe JP Jr, Adler LP, Shenk RR, Sunshine J: Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994, 1:132-140.
43. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, Tilbury RS: Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993, 71:3920-3925.
44. 18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996, 23:618-623.
45. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA: The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992, 216:27-34.
46. Wahl RL, Cody RL, Hutchins GD, Mudgett EE: Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991, 179:765-770.
47. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M: Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000, 18: 3495-3502.
48. Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nussle K, Koretz K, Glatting G, Rieber A, Kreienberg R, et al.: Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001, 28:351-358.
49. 18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Eur Radiol 2001, 11:2058-2070.
50. Weinberg I, Majewski S, Weisenberger A, Markowitz A, Aloj L, Majewski L, Danforth D, Mulshine J, Cowan K, Zujewski J, et al.: Preliminary results for positron emission mammography: real-time functional breast imaging in a conventional mammography gantry. Eur J Nucl Med 1996, 23:804-806.
51. Murthy K, Aznar M, Thompson CJ, Loutfi A, Lisbona R, Gagnon JH: Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med 2000, 41:1851-1858.
52. Levine EA, Freimanis RI, Perrier ND, Morton K, Lesko NM, Bergman S, Geisinger KR, Williams RC, Sharpe C, Zavarzin V, et al.: Positron emission mammography: initial clinical results. Ann Surg Oncol 2003, 10:86-91.
53. Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman RE: Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology 2005, 234:527-534.
54. Weinberg IN, Beylin D, Zavarzin V, Yarnall S, Stepanov PY, Anashkin E, Narayanan D, Dolinsky S, Lauckner K, Adler LP: Positron emission mammography: high-resolution biochemical breast imaging. Technol Cancer Res Treat 2005, 4:55-60.
55. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR: Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 1997, 203:323-327.
56. Avril N, Dose J, Janicke F, Bense S, Ziegler S, Laubenbacher C, Romer W, Pache H, Herz M, Allgayer B, et al.: Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996, 14: 1848-1857.
57. Utech CI, Young CS, Winter PF: Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996, 23:1588-1593.
58. Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R, Micheli A, Asero S, Ferraris C, Gennaro M, et al.: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001, 93:630-635.
59. Fehr MK, Hornung R, Varga Z, Burger D, Hess T, Haller U, Fink D, von Schulthess GK, Steinert HC: Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 2004, 10:89-93.
60. Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S: Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 2003, 10:622-627.
61. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG, Group PETS: Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004, 22:277-285.
62. Lovrics PJ, Chen V, Coates G, Cornacchi SD, Goldsmith CH, Law C, Levine MN, Sanders K, Tandan VR: A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 2004, 11:846-853.
63. 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997, 17:1687-1692.
64. Kim TS, Moon WK, Lee DS, Chung JK, Lee MC, Youn YK, Oh SK, Choe KJ, Noh DY: Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 2001, 25:829-834.
65. Moon D, Hoh C, Silverman D, Glaspy J, Phelps M, Maddahi J: Accuracy of whole-body FDG PET for the detection of recurrent or metastatic breast carcinoma [abstract]. J Nucl Med 1996, 37:99P.
66. Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W: The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 2003, 23:1859-1867.
67. Suarez M, Perez-Castejon MJ, Jimenez A, Domper M, Ruiz G, Montz R, Carreras JL: Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002, 46:113-121.
68. 18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003, 129:147-153.
69. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001, 19:3516-3523.
70. Ahmad A, Barrington S, Maisey M, Rubens RD: Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999, 79:478-482.
71. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998, 16:3375-3379.
72. 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002, 128:325-328.
73. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993, 11:2101-2111.
74. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J: Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995, 13:1470-1477.
75. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000, 18:1676-1688.
76. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000, 18: 1689-1695.
77. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ Schubert EK, Tseng J, Livingston RB: Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002, 43:500-509.
78. Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB, Mankoff DA: Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002, 9:913-921.
79. Van de Wiele C, De Vos F, Slegers G, Van Belle S, Dierckx RA: Radiolabeled estradiol derivatives to predict response to hormonal treatment in breast cancer: a review. Eur J Nucl Med 2000, 27:1421-1433.
80. 123I]iodovinyl-11 beta-methoxyestradiol (MIVE2) - Part II. Preliminary results in patients with breast carcinoma. Int J Radiat Applic Instrum B Nucl Med Biol 1992, 19:263-267.
81. 99mTc-methoxyisobutyl isonitrile in the characterization of breast tumors. J Nucl Med 2000, 41:1324-1331.
82. Bennink RJ, van Tienhoven G, Rijks LJ, Noorduyn AL, Janssen AG, Sloof GW: In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. J Nucl Med 2004, 45:1-7.
83. Kieswetter D, Katzenellenbogen J, Kilbourn M, Welch M: Fluorine-18 labeled estrogen: stereochemical and radiochemical considerations in the preparation of fluorine-18 labeled 16-fluoro estrogens by fluoride ion displacement reactions. J Org Chem 1984, 49:4900-4905.
84. Tewson T Synthesis of 16-alpha-fluoroestradiol (abstract). J Nucl Med 1983, 24:P52.
85. Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA: Breast cancer: PET imaging of estrogen receptors. Radiology 1988, 169:45-48.
86. 18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991, 32:1526-1531.
87. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, Detert DD, Cutler PD, Katzenellenbogen JA, Welch MJ: Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995, 36:1766-1774.
88. 18F]difluoroestradiols and their 11beta-methoxy derivatives for estrogen receptor imaging. J Labelled Cpd Radiopharm 2001, 44:S348-S350.
89. Seimbille Y, Bénard F, van Lier JE: Synthesis of 16alpha-fluoro ICI 182,780 derivatives: powerful antiestrogens to image estrogen receptor densities in breast cancer by positron emission tomography. J Chem Soc Perkin Trans I 2002, 20: 2275-2281.
90. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 2002, 67:766-775.
91. 18F]fluorine substitution at the 16alpha-position of fulvestrant (Faslodex; ICI 182,780). Nucl Med Biol 2004, 31:691-698.
92. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ: Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001, 19:2797-2803.
93. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL: Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002, 43:1210-1217.
94. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002, 8:3315-3323.
95. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004, 31:720-724.
96. Amano S, Inoue T, Tomiyishi K, Ando T, Endo K: In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med 1998, 39:1424-1427.
97. Huovinen R, Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M: Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer 1993, 67:787-791.
98. 18F]fluorotamoxifen for imaging breast tumors. J Drug Target 1993, 1:259-267.
99. 11C]tyrosine PET. J Nucl Med 1997, 38:692-696.
100. Vilner BJ, John CS, Bowen WD: Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995, 55:408-413.
101. John CS, Vilner BJ, Schwartz AM, Bowen WD: Characterization of sigma receptor binding sites in human biopsied solid tumors [abstract]. J Nucl Med 1996, 37:267P.
102. Simony-Lafontaine J, Esslimani M, Bribes E, Gourgou S, Lequeux N, Lavail R, Grenier J, Kramar A, Casellas P: Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors. Br J Cancer 2000, 82:1958-1966.
103. 125I]MBA) for imaging breast cancer. Nucl Med Biol 1999, 26:377-382.
104. 125I]-N-(N-benzylpiperidin-4-yl)-4- iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells. J Medicinal Chem 1994, 37:1737-1739.
105. 125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity sigma receptor ligand for potential imaging of breast cancer. Cancer Res 1995, 55:3022-3027.
106. 123I-iodo -4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results. J Nucl Med 2002, 43:1647-1649.
107. 18F]-1-(3fluoropropyl)-4- (4-cyanophenoxymethyl)-piperidine:a potential sigma-1 receptor radioligand for PET. J Labelled Cpd Radiopharm 1996, 38:785-793.
108. 18F]FPS in the MMTV transgenic mouse breast cancer model [abstract]. J Nucl Med 2003, 44:371P.
109. 18F]fluorobenzamide: a potential ligand for PET imaging of breast cancer. Nucl Med Biol 2000, 27:763-767.
110. 18F]fluorobenzamide: a potential ligand for PET imaging of sigma receptors. Nucl Med Biol 1997, 24:671-676.
111. 76Br] (4 isothiocyanatobenzyl-ammonio) -bro mo-decahydro-closo-dodecaborate (Bromo-DABI). Nucl Med Biol 2004, 31:205-211.
112. 11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol 2002, 29:761-770.
113. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24:389-427.